NDAINTRAVENOUSSOLUTION
Approved
Mar 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
VERAPAMIL HYDROCHLORIDE (verapamil hydrochloride) by Teva is clinical pharmacology verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) that exerts its pharmacologic effects by modulating the influx of ionic calcium across the cell membrane of the arterial smooth muscle as well as in conductile and contractile myocardial cells. First approved in 1984.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker) administered intravenously that modulates calcium transport across cell membranes in arterial smooth muscle and myocardial tissue. It is indicated for angina (including vasospastic and unstable variants), arrhythmia management (atrial fibrillation/flutter rate control, paroxysmal supraventricular tachycardia), and essential hypertension. The drug works by reducing coronary artery spasm, decreasing myocardial oxygen demand, and slowing AV node conduction.
LOE Approaching
Product approaching loss of exclusivity with significant competitive pressure (30/100); teams should focus on operational efficiency and managed transition strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) that exerts its pharmacologic effects by modulating the influx of ionic calcium across the cell membrane of the arterial smooth muscle as well as in conductile and…
Worked on VERAPAMIL HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.